GLI2 and colonic neoplasm: Other studies reported that GANT-61 inhibits GLI1/GLI2 in colon cancer cells that are resistant to the SMO inhibitors cyclopamine and GDC-0449; this observation suggests SMO-independent Hh signaling pathway activation in colon cancer [38].